DGIdb - LEVODOPA Drug Record

LEVODOPA chembl:CHEMBL1009 Approved

Alternate Names:

LARODOPA
BENDOPA
LEVODOPA
BROCADOPA
NSC-118381
DOPAR
V-1512
INBRIJA
(−)-DOPA
L-BETA-(3,4-DIHYDROXYPHENYL)ALANINE
Β-(3,4-DIHYDROXYPHENYL)-L-ALANINE
L-3,4-DIHYDROXYPHENYLALANINE
SINEMET®
L-DOPA
3-HYDROXY-L-TYROSINE
LDP540
LEVODOPUM
3,4-DIHYDROXY-L-PHENYLALANINE
Β-(3,4-DIHYDROXYPHENYL)ALANINE
(−)-3-(3,4-DIHYDROXYPHENYL)-L-ALANINE
DIHYDROXY-L-PHENYLALANINE
chembl:CHEMBL1009
drugbank:01235
chemidplus:59-92-7
rxcui:6375
pubchem.compound:6047

Drug Info:

Drug Class	antiparkinson agents
Year of Approval	approved before 1982
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiparkinson agent

(5 More Sources)

Publications:

Damasceno Dos Santos EU et al., 2019, Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease., J Clin Pharmacol
Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J
Koller et al., 1998, Mechanism of action of dopaminergic agents in Parkinson's disease., Neurology
Onofrj et al., 2008, An expert opinion on safinamide in Parkinson's disease., Expert Opin Investig Drugs
Deleu et al., 2002, Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease., Clin Pharmacokinet
Zappia et al., 2005, Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study., Arch. Neurol.
Kovoor et al., 2005, D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways., J. Neurosci.
Mori et al., 2005, Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice., Neurosci. Res.
Dupre et al., 2007, The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat., Brain Res.
Schumacher-Schuh AF et al., 2014, Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients., Pharmacogenomics J
St-Hilaire et al., 2006, Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice., Eur. J. Neurosci.
St-Hilaire et al., 2005, Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism., Neurobiol. Dis.
Gangemi et al., 2003, Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease., Mediators Inflamm.
Joyce et al., 2004, Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment., Exp. Neurol.
Adams et al., 1994, Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats., Exp. Neurol.
Baraczka et al., 1983, Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration., J. Neural Transm.
Pavón et al., 2006, ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice., Biol. Psychiatry
Nash et al., 2005, Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia., FASEB J.
Lee et al., 2006, A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats., Neuropharmacology
Vila et al., 1997, Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA., J. Neurosci.
Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
Cheng et al., 1998, Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule., Am. J. Physiol.
Takezako et al., 2001, Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine., J. Am. Soc. Nephrol.
Moreau C et al., 2015, Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease., Brain
Liu S et al., 2014, The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study., Pharmacogenet Genomics
Liu et al., 2004, Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells., Neurochem. Res.

LEVODOPA MT-CO1

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8987798

Sources:
NCI
LEVODOPA DLG4

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15703272

Sources:
NCI
LEVODOPA HOMER1

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24126708

Sources:
PharmGKB
LEVODOPA IL15

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14514477

Sources:
NCI
LEVODOPA DRD5

Interaction Score: 0.53

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name entacapone/levodopa/carbidopa,Stalevo

Novel drug target Established target

Trial Name levodopa + carbidopa,Duodopa

PMIDs:
9633680 18549347 11978145

Sources:
TdgClinicalTrial
LEVODOPA NR4A1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16930409 15896973

Sources:
NCI
LEVODOPA DBH

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24809448

Sources:
PharmGKB
LEVODOPA ADA

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11134247

Sources:
NCI
LEVODOPA DRD3

Interaction Score: 0.21

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine D3 receptor agonist

Direct Interaction yes

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
30794329 27779245 9633680 18549347 11978145

Sources:
TdgClinicalTrial ChemblInteractions PharmGKB
LEVODOPA DRD4

Interaction Score: 0.16

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name entacapone/levodopa/carbidopa,Stalevo

Novel drug target Established target

Trial Name levodopa + carbidopa,Duodopa

PMIDs:
9633680 18549347 11978145

Sources:
TdgClinicalTrial
LEVODOPA MTHFR

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12083967

Sources:
PharmGKB
LEVODOPA DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name DM-1992

Novel drug target Established target

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
27779245 15824260 15728856 15710490 18549347 9633680 11978145 17553470

Sources:
TdgClinicalTrial TEND PharmGKB TTD
LEVODOPA SLC22A1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LEVODOPA MAOB

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7867755 6420516

Sources:
NCI
LEVODOPA TRPV1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16806299

Sources:
NCI
LEVODOPA BAX

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15672541

Sources:
NCI
LEVODOPA AGTR1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9458818

Sources:
NCI
LEVODOPA SLC6A3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25805645

Sources:
PharmGKB
LEVODOPA DRD1

Interaction Score: 0.07

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name DM-1992

Novel drug target Established target

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
9633680 18549347 11978145

Sources:
DTC TdgClinicalTrial TEND
LEVODOPA COMT

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LEVODOPA BDNF

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15081599

Sources:
NCI
LEVODOPA MAPK1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16139809

Sources:
NCI
LEVODOPA WRN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA BLM

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA MPHOSPH8

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA POLH

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA RECQL

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA APEX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA CBX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA FEN1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA POLI

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA POLK

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA KDM4E

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA HSD17B10

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA KDM4A

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEVODOPA EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: LEVODOPA
- Version: 01-August-2011
Alternate Names:

LEVODOPA Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class antiparkinson agents

Publications:
TdgClinicalTrial: LEVODOPA
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiparkinson agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: L-DOPA

Version: 14-September-2017

Alternate Names:

C611 NCI drug code

Drug Info:

Publications:

Nash et al., 2005, Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia., FASEB J.

Takezako et al., 2001, Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine., J. Am. Soc. Nephrol.

Cheng et al., 1998, Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule., Am. J. Physiol.

NCI: LEVODOPA

Version: 14-September-2017

Alternate Names:

C611 NCI drug code

Drug Info:

Publications:

Liu et al., 2004, Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells., Neurochem. Res.

Adams et al., 1994, Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats., Exp. Neurol.

Vila et al., 1997, Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA., J. Neurosci.

PharmGKB: levodopa

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J

Moreau C et al., 2015, Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease., Brain

Damasceno Dos Santos EU et al., 2019, Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease., J Clin Pharmacol

TTD: Levodopa
- Version: 2020.06.01
Alternate Names:

D08HVR TTD Drug ID

Drug Info:

Publications:
DTC: LEVODOPA
- Version: 02-September-2020
Alternate Names:

CHEMBL1009 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1009
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1009
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	entacapone/levodopa/carbidopa,Stalevo
Novel drug target	Established target
Trial Name	levodopa + carbidopa,Duodopa

Mechanism of Interaction	Dopamine D3 receptor agonist
Direct Interaction	yes
Trial Name	entacapone/levodopa/carbidopa,Stalevo

Trial Name	DM-1992
Novel drug target	Established target
Trial Name	entacapone/levodopa/carbidopa,Stalevo

LEVODOPA Drug Record

LEVODOPA chembl:CHEMBL1009 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8987798

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15703272

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24126708

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14514477

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name entacapone/levodopa/carbidopa,Stalevo Novel drug target Established target Trial Name levodopa + carbidopa,Duodopa

PMIDs: 9633680 18549347 11978145

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16930409 15896973

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24809448

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11134247

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Dopamine D3 receptor agonist Direct Interaction yes Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs: 30794329 27779245 9633680 18549347 11978145

Sources: TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name entacapone/levodopa/carbidopa,Stalevo Novel drug target Established target Trial Name levodopa + carbidopa,Duodopa

PMIDs: 9633680 18549347 11978145

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12083967

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name DM-1992 Novel drug target Established target Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs: 27779245 15824260 15728856 15710490 18549347 9633680 11978145 17553470

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7867755 6420516

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16806299

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15672541

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9458818

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25805645

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name DM-1992 Novel drug target Established target Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs: 9633680 18549347 11978145

Interaction Types & Directionality:

n/a

PMIDs:
8987798

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15703272

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24126708

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
14514477

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name entacapone/levodopa/carbidopa,Stalevo

Novel drug target Established target

Trial Name levodopa + carbidopa,Duodopa

PMIDs:
9633680 18549347 11978145

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
16930409 15896973

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24809448

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11134247

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Dopamine D3 receptor agonist

Direct Interaction yes

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
30794329 27779245 9633680 18549347 11978145

Sources:
TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name entacapone/levodopa/carbidopa,Stalevo

Novel drug target Established target

Trial Name levodopa + carbidopa,Duodopa

PMIDs:
9633680 18549347 11978145

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
12083967

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name DM-1992

Novel drug target Established target

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
27779245 15824260 15728856 15710490 18549347 9633680 11978145 17553470

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
7867755 6420516

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16806299

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15672541

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9458818

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25805645

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name DM-1992

Novel drug target Established target

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
9633680 18549347 11978145

Sources:
DTC TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15081599

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16139809

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC